StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research note released on Tuesday morning. The firm issued a sell rating on the stock.
A number of other analysts have also recently issued reports on OCX. Needham & Company LLC reiterated a buy rating and set a $4.25 target price on shares of OncoCyte in a report on Thursday, May 16th. Benchmark reaffirmed a speculative buy rating and set a $5.00 price target on shares of OncoCyte in a research report on Monday, April 15th. Finally, Stephens restated an equal weight rating and set a $4.00 price objective on shares of OncoCyte in a research note on Wednesday, April 17th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, OncoCyte currently has a consensus rating of Hold and an average target price of $4.06.
View Our Latest Research Report on OCX
OncoCyte Price Performance
OncoCyte (NASDAQ:OCX – Get Free Report) last issued its quarterly earnings results on Wednesday, May 15th. The company reported ($1.13) EPS for the quarter. The firm had revenue of $0.18 million for the quarter. OncoCyte had a negative return on equity of 135.45% and a negative net margin of 2,905.14%. Research analysts predict that OncoCyte will post -2.58 earnings per share for the current year.
About OncoCyte
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.
Featured Articles
- Five stocks we like better than OncoCyte
- How to Start Investing in Real Estate
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- Bank Stocks – Best Bank Stocks to Invest In
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- What Are the FAANG Stocks and Are They Good Investments?
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.